![Hitto Kaufmann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hitto Kaufmann
Direttore Tecnico/Scientifico/R&S presso HANSA BIOPHARMA AB
Profilo
Hitto Kaufmann is currently the Vice Chairman at the European Society For Animal Cell Technology and the Co-Managing Director at Pieris Pharmaceuticals GmbH.
He is also the Chief Scientific Officer at Hansa Biopharma AB, starting in 2023.
Previously, he worked as the Global Head-Strategy & Operations at Sanofi from 2018 to 2019.
He also held the position of Vice President-Process Science at Boehringer Ingelheim Corp.
His most recent former position was as the Chief Scientific Officer & Senior Vice President at Pieris Pharmaceuticals, Inc. from 2019 to 2023.
Dr. Kaufmann received his graduate degree from The Scripps Research Institute and his doctorate degree from the Swiss Federal Institute of Technology.
He also holds a graduate degree from Technische Universität Braunschweig.
Ultime notizie su Hitto Kaufmann
Posizioni attive di Hitto Kaufmann
| Società | Posizione | Inizio |
|---|---|---|
| HANSA BIOPHARMA AB | Direttore Tecnico/Scientifico/R&S | 01/12/2023 |
| European Society For Animal Cell Technology | Direttore/Membro del Consiglio | - |
Pieris Pharmaceuticals GmbH
 Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Amministratore Delegato | - |
Precedenti posizioni note di Hitto Kaufmann
| Società | Posizione | Fine |
|---|---|---|
| PIERIS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/11/2023 |
| SANOFI | Direttore operativo | 02/01/2019 |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | - |
Formazione di Hitto Kaufmann
| Technische Universität Braunschweig | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
| The Scripps Research Institute | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| SANOFI | Health Technology |
| HANSA BIOPHARMA AB | Health Technology |
| Aziende private | 3 |
|---|---|
| European Society For Animal Cell Technology | |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Pieris Pharmaceuticals GmbH
Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Health Technology |
- Borsa valori
- Insiders
- Hitto Kaufmann
